Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 875 of 885 entries
View as:

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05550532 Org: User:
Start: 12/06/22 End: 11/13/24 Due: 11/13/25

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase: N/A Priority: Normal
NCT ID: NCT01715285 Org: User:
Start: 02/12/13 End: 02/13/22 Due: 02/13/23

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Phase: N/A Priority: Normal
NCT ID: NCT03381196 Org: User:
Start: 01/21/18 End: 08/24/20 Due: 08/24/21

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Phase: N/A Priority: Normal
NCT ID: NCT03371381 Org: User:
Start: 01/02/18 End: 10/09/18 Due: 10/09/19

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase: N/A Priority: Normal
NCT ID: NCT03201965 Org: User:
Start: 10/05/17 End: 11/19/24 Due: 11/19/25

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02329847 Org: User:
Start: 03/11/15 End: 02/09/22 Due: 02/09/23

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT05242484 Org: User:
Start: 09/19/22 End: 03/27/29 Due: 03/27/30

A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04087759 Org: User:
Start: 09/16/19 End: 01/07/20 Due: 01/07/21

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase: N/A Priority: Normal
NCT ID: NCT05663866 Org: User:
Start: 05/18/23 End: 10/29/25 Due: 10/29/26

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase: N/A Priority: Normal
NCT ID: NCT03628924 Org: User:
Start: 09/04/18 End: 05/22/20 Due: 05/22/21

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03431350 Org: User:
Start: 03/02/18 End: 12/31/25 Due: 12/31/26

A Study of JNJ-68179280 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04844463 Org: User:
Start: 05/26/21 End: 03/13/23 Due: 03/13/24

A Study of Guselkumab in Participants With Active Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT04376827 Org: User:
Start: 09/15/20 End: 02/01/23 Due: 02/01/24

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

Phase: N/A Priority: Normal
NCT ID: NCT02945007 Org: User:
Start: 11/08/16 End: 01/16/20 Due: 01/16/21

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Phase: N/A Priority: Normal
NCT ID: NCT02025907 Org: User:
Start: 02/28/14 End: 09/30/15 Due: 09/30/16

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02221726 Org: User:
Start: 08/31/14 End: 08/31/14 Due: 08/31/15

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00574288 Org: User:
Start: 03/26/08 End: 04/03/17 Due: 04/03/18

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02295865 Org: User:
Start: 11/17/14 End: 03/11/16 Due: 03/11/17

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03664232 Org: User:
Start: 11/07/18 End: 10/28/22 Due: 10/28/23

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT02885454 Org: User:
Start: 08/31/16 End: 12/31/16 Due: 12/31/17

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Phase: N/A Priority: Normal
NCT ID: NCT00929188 Org: User:
Start: 10/31/09 End: 01/31/15 Due: 01/31/16

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Phase: N/A Priority: Normal
NCT ID: NCT02927925 Org: User:
Start: 02/14/17 End: 01/07/20 Due: 01/07/21

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01689623 Org: User:
Start: 06/30/12 End: 08/31/12 Due: 08/31/13

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01529515 Org: User:
Start: 05/31/12 End: 04/30/14 Due: 04/30/15

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01707316 Org: User:
Start: 06/30/12 End: 08/31/12 Due: 08/31/13